Buy
Sell
Share Name Share Symbol Market Type
Abbvie Inc. NYSE:ABBV NYSE Ordinary Share
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  +$0.71 +0.88% $81.59 $81.75 $79.88 $80.51 4,218,954 00:27:25

AbbVie Glioblastoma Drug Misses Primary Endpoint

17/05/2019 2:31pm

Dow Jones News


AbbVie Inc. (NYSE:ABBV)
Historical Stock Chart

1 Month : From Apr 2019 to May 2019

Click Here for more AbbVie Inc. Charts.

By Chris Wack

 

AbbVie (ABBV) said Friday that its phase 3 study of its glioblastoma drug depatuxizumab mafodotin didn't meet its primary endpoint.

The biopharmaceutical company said its Intellance-1 study of depatuxizumab mafodotin in patients with newly diagnosed glioblastoma failed to achieve its overall survival objective, and demonstrated no survival benefit for patients receiving Depatux-M at an interim analysis.

Abbvie said an independent data monitoring committee recommended the study be stopped due to lack of survival benefit for patients receiving Depatux-M compared with the placebo when added to the standard regimen of radiation and temozolomide.

AbbVie said no new safety findings were observed, and enrollment in all ongoing Depatux-M studies has been halted.

The Intellance-1 trial was conducted in collaboration with the RTOG Foundation, an independent, non-profit cancer research organization.

Glioblastoma, also known as glioblastoma multiforme, is an aggressive type of cancer that can occur in the brain or spinal cord.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

May 17, 2019 09:16 ET (13:16 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

1 Year AbbVie Inc. Chart

1 Year AbbVie Inc. Chart

1 Month AbbVie Inc. Chart

1 Month AbbVie Inc. Chart
Your Recent History
NYSE
ABBV
AbbVie Inc..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20190522 23:49:53